Page last updated: 2024-08-16

mitomycin and bortezomib

mitomycin has been researched along with bortezomib in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cassidy, J; Hochster, H1
Bartlett, DL; Choudry, HA; Dilly, AK; Kwon, YT; Lee, YJ; Song, X1
Chng, WJ; Chow, EK; Ho, CM; Ho, D; Hooi, L; Jha, S; Karnani, N; Rashid, MBMA; Silva, A; Tan, PF; Teh, AL; Toh, TB; Zhang, Y1

Reviews

2 review(s) available for mitomycin and bortezomib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes

2003

Other Studies

3 other study(ies) available for mitomycin and bortezomib

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.
    Molecular cancer research : MCR, 2015, Volume: 13, Issue:12

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Bortezomib; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Mitochondria; Mitomycin; Phosphorylation; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Science translational medicine, 2018, 08-08, Volume: 10, Issue:453

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; High-Throughput Screening Assays; Humans; Mice; Mitomycin; Multiple Myeloma; Phenotype; Protein Tyrosine Phosphatase, Non-Receptor Type 6; RNA, Messenger; Tumor Burden

2018